Rigel (RIGL) EVP Santos uses shares to cover equity tax liability

Rhea-AI Filing Summary

Rigel Pharmaceuticals executive David A. Santos reported a routine share disposition related to tax withholding. On 02/10/2026, 3,546 shares of common stock were disposed of at $34.62 per share to satisfy tax obligations associated with equity compensation. After this transaction, he directly owned 43,440 shares of Rigel common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Santos David A

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	3,546	$34.62	$123K

Holdings After Transaction: Common Stock — 43,440 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos David A

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		3,546	D	$34.62	43,440	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Raymond Furey (Attorney-in-Fact)	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RIGL executive David A. Santos report?

David A. Santos reported a tax-withholding disposition of 3,546 shares of Rigel Pharmaceuticals common stock. The transaction occurred on February 10, 2026, and used shares to cover tax liabilities tied to equity compensation rather than representing an open-market sale.

At what price were the RIGL shares used for tax withholding valued?

The 3,546 Rigel Pharmaceuticals shares were valued at $34.62 per share for the tax-withholding disposition. This valuation determines how many shares were needed to satisfy the tax liability connected to the executive’s equity-based compensation event.

How many RIGL shares does David A. Santos own after this Form 4 transaction?

Following the reported transaction, David A. Santos directly owned 43,440 shares of Rigel Pharmaceuticals common stock. This figure reflects his beneficial ownership after using 3,546 shares to cover tax obligations associated with his equity compensation.

What does transaction code F mean in the RIGL Form 4 filing?

Transaction code F indicates a disposition of shares to pay the exercise price or tax liability by delivering securities. For RIGL, it shows that David A. Santos used 3,546 shares to satisfy taxes on an equity compensation event, not a discretionary market sale.

Is the Santos Form 4 transaction for RIGL a direct or indirect holding change?

The Form 4 shows the transaction affecting a direct ownership position in Rigel Pharmaceuticals common stock. After the tax-withholding disposition, David A. Santos directly held 43,440 shares, with no indirect ownership nature disclosed in this filing.

What is the role of David A. Santos at Rigel Pharmaceuticals (RIGL)?

David A. Santos is identified as an EVP, Chief Commercial Officer of Rigel Pharmaceuticals. His Form 4 filing reflects changes in his directly held common stock position resulting from a tax-withholding share disposition tied to his equity compensation.